Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Dynavax Technologies Corp (NASDAQ: DVAX) closed the day trading at $15.37 down -0.07% from the previous closing price of $15.38. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 6.81 million shares were traded. DVAX stock price reached its highest trading level at $15.3925 during the session, while it also had its lowest trading level at $15.37.
Ratios:
For a better understanding of DVAX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.41. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 7.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.46.
Upgrades & Downgrades
In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Sell and sets its target price to $12 from $15 previously.
On February 01, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 27, 2022, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 24 ’25 when Novack David F sold 30,000 shares for $15.49 per share. The transaction valued at 464,700 led to the insider holds 111,451 shares of the business.
DAVID NOVACK bought 30,000 shares of DVAX for $464,700 on Dec 24 ’25. On Aug 22 ’25, another insider, Myers Scott Dunseth, who serves as the Director of the company, bought 3,800 shares for $10.82 each. As a result, the insider paid 41,116 and bolstered with 35,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1804821760 and an Enterprise Value of 1446229760. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.46 while its Price-to-Book (P/B) ratio in mrq is 3.38. Its current Enterprise Value per Revenue stands at 4.376 whereas that against EBITDA is 59.734.
Stock Price History:
The Beta on a monthly basis for DVAX is 0.93, which has changed by 0.20438528 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $15.49, while it has fallen to a 52-week low of $9.20. The 50-Day Moving Average of the stock is 38.89%, while the 200-Day Moving Average is calculated to be 42.46%.
Shares Statistics:
Over the past 3-months, DVAX traded about 2.14M shares per day on average, while over the past 10 days, DVAX traded about 5135220 shares per day. A total of 117.36M shares are outstanding, with a floating share count of 116.65M. Insiders hold about 0.66% of the company’s shares, while institutions hold 97.44% stake in the company. Shares short for DVAX as of 1765756800 were 12289867 with a Short Ratio of 5.75, compared to 1763078400 on 13723263. Therefore, it implies a Short% of Shares Outstanding of 12289867 and a Short% of Float of 15.75.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Dynavax Technologies Corp (DVAX) in the stock market.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.5 and -$0.5 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is $0.33, with 1.0 analysts recommending between $0.33 and $0.33.
Revenue Estimates
3 analysts predict $80.26M in revenue for. The current quarter. It ranges from a high estimate of $82.09M to a low estimate of $77.49M. As of. The current estimate, Dynavax Technologies Corp’s year-ago sales were $72.03MFor the next quarter, 3 analysts are estimating revenue of $84.68M. There is a high estimate of $94M for the next quarter, whereas the lowest estimate is $72.03M.
A total of 3 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $340.58M, while the lowest revenue estimate was $335.98M, resulting in an average revenue estimate of $338.75M. In the same quarter a year ago, actual revenue was $277.25MBased on 3 analysts’ estimates, the company’s revenue will be $392.42M in the next fiscal year. The high estimate is $417.12M and the low estimate is $360.14M.
